Abstract
Combined anti-PD-L1+anti-CTLA-4 therapy has shown benefits over anti-PD-L1 monotherapy as a neoadjuvant treatment in head and neck cancer. In this issue of Immunity, Franken etal. report that CD4+ Tcell trafficking from lymph nodes to tumors and expansion toward T helper 1 cells are features specific to combination therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have